C. Kurkjian

发表

S. E. Lind, C. Kurkjian, S. Lind, 2007 .

DNA methylation: its role in cancer development and therapy.

S. Kummar, A. Murgo, Shivaani Kummar, 2008, Current problems in cancer.

Antitumor Synergism and Enhanced Survival with a Tumor Vasculature–Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide

V. Sikavitsas, K. Fung, R. Harrison, 2017, Molecular Cancer Therapeutics.

Abstract B218: Drug-drug interaction assessment of GDC-0032, a beta-sparing inhibitor of phosphoinositide 3-kinase (PI3K), using midazolam, a sensitive CYP3A4 substrate.

J. Baselga, D. Juric, J. Infante, 2013 .

Small cell lung cancer and other thoracic malignancies

M. Nishimura, Y. Hosomi, M. Shibuya, 2012 .

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.

R. Kurzrock, Philippe Bédard, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy.

S. Kummar, A. Murgo, C. Kurkjian, 2008, Clinical colorectal cancer.

Risks and benefits with bevacizumab: evidence and clinical implications

Edward S. Kim, C. Kurkjian, 2012, Therapeutic advances in drug safety.

The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors.

Suzanne F. Jones, J. Bendell, H. Burris, 2012 .

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors

H. Burris, J. Infante, L. Siu, 2018, Investigational New Drugs.

Antitumor Activity of an Enzyme Prodrug Therapy Targeted to the Breast Tumor Vasculature

V. Sikavitsas, R. Harrison, C. Kurkjian, 2013, Cancer investigation.

Abstract PD1-3: Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer

J. Baselga, T. Wilson, D. Juric, 2013 .

Mitosis-targeting natural products for cancer prevention and therapy.

C. Rao, Hiroshi Y Yamada, C. Kurkjian, 2012, Current drug targets.

Immunology of the Lymphomas

H. Ozer, C. Kurkjian, 2013 .

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

Suzanne F. Jones, R. Neuwirth, L. Hart, 2017, Cancer Chemotherapy and Pharmacology.

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2015, Investigational new drugs.

Advances in the Treatment of Metastatic Colorectal Cancer

S. Kummar, C. Kurkjian, 2009, American journal of therapeutics.

Symptomatic metastases to the pituitary infundibulum resulting from primary breast cancer

R. Kamble, H. Ozer, M. Kharfan-Dabaja, 2005, International Journal of Clinical Oncology.

A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.

Suzanne F. Jones, J. Bendell, H. Burris, 2016, European journal of cancer.

A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC)

G. Giaccone, P. Choyke, J. Doroshow, 2008 .

Targeted enzyme prodrug therapy for metastatic prostate cancer – a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase

R. Harrison, C. Kurkjian, Katrin P. Guillen, 2014, Journal of Biomedical Science.

Cytogenetic changes associated with myelodysplastic syndrome affecting bone marrow engraftment analysis.

R. Kamble, M. Kharfan-Dabaja, C. Kurkjian, 2006, The Journal of molecular diagnostics : JMD.

Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer

R. Harrison, C. Kurkjian, Katrin P. Guillen, 2015, Pancreas.

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2014, Cancer.

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2013, Investigational New Drugs.

ME-143, a novel inhibitor of tumor-specific NADH oxidase (tNOX): Results from a first-in-human phase I study.

Suzanne F. Jones, J. Bendell, H. Burris, 2012 .

The observation that changes in DNA methylation potentially play a role in neoplastic transformation has existed for nearly 30 years. Foreword.

S. Kummar, A. Murgo, C. Kurkjian, 2008, Current problems in cancer.

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Suzanne F. Jones, Yulei N. Wang, J. Bendell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach

J. Bendell, C. Kurkjian, S. Pant, 2017, Cancer investigation.

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Suzanne F. Jones, C. Rudin, G. Shapiro, 2019, Investigational New Drugs.

A phase II study of the c-Met inhibitor tivantinib (tiv) in combination with FOLFOX for the treatment of patients (pts) with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach.

J. Bendell, C. Kurkjian, S. Pant, 2015 .

Impact of Health Care Insurance Status on Treatment Outcomes of Acute Myeloid Leukemia

S. Vesely, D. Thompson, C. Kurkjian, 2017, Clinical lymphoma, myeloma & leukemia.

Evaluation of tolerability and anti-tumor activity of GDC-0032, a PI3K inhibitor with enhanced activity against PIK3CA mutant tumors, administered-to patients with advanced solid tumors

J. Baselga, T. Wilson, D. Juric, 2013 .

The effects of licofelone, a dual lipoxygenase and cyclooxygenase inhibitor, with and without rosiglitazone in human MCF-7 and MDA-MB-231 breast cancer cells

C. Rao, S. Guruswamy, H. Ozer, 2007 .

Abstract B75: A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.

A. El-Khoueiry, J. Bendell, I. Chang, 2013 .

Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors.

Suzanne F. Jones, C. Liang, J. Bendell, 2012 .

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Y. Wang, J. Bendell, L. Camacho, 2014 .

Acute promyelocytic leukemia and constitutional trisomy 21.

S. T. Dunn, R. Kamble, M. Kharfan-Dabaja, 2006, Cancer genetics and cytogenetics.

Short communication Acute promyelocytic leukemia and constitutional trisomy 21

S. T. Dunn, R. Kamble, M. Kharfan-Dabaja, 2006 .

Topics in clinical pharmacology: renal, gastrointestinal, and pain management.

S. Kummar, R. Barkin, K. Waxman, 2010, Disease-a-month : DM.

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Suzanne F. Jones, C. Rudin, G. Shapiro, 2019, Investigational New Drugs.

A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors.

M. Birrer, P. LoRusso, K. Sankhala, 2013 .

Phase I/II Study to Assess the Safety, Pharmacokinetics (PK) and Efficacy of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Carboplatin/Etoposide in Patients with Solid Tumors Including Small-Cell Lung Cancer (SCLC)

A. Argiris, J. Bendell, A. Mita, 2012 .

Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy.

S. Kummar, A. Murgo, C. Kurkjian, 2008, Clinical colorectal cancer.